טוען...
Tumor Volume Decrease at 8 weeks is Associated with Longer Survival in EGFR-mutant Advanced Non-Small-Cell Lung Cancer Patients treated with EGFR Tyrosine Kinase Inhibitor
BACKGROUND: The study investigated if tumor volume changes at 8 weeks of therapy are associated with outcomes in advanced NSCLC patients with sensitizing EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: In 56 advanced NSCLC patients with sensitizing EGFR muta...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3714311/ https://ncbi.nlm.nih.gov/pubmed/23787800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318294c909 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|